vs

Side-by-side financial comparison of BIODESIX INC (BDSX) and Ballard Power Systems Inc. (BLDP). Click either name above to swap in a different company.

BIODESIX INC is the larger business by last-quarter revenue ($28.8M vs $17.7M, roughly 1.6× Ballard Power Systems Inc.). Ballard Power Systems Inc. runs the higher net margin — 994.4% vs -13.8%, a 1008.3% gap on every dollar of revenue.

Biodesix Inc is a molecular diagnostics enterprise specializing in developing and commercializing innovative blood-based testing solutions for oncology and infectious disease fields. It primarily serves healthcare providers, biopharmaceutical partners and patients across North America, with core business covering personalized medicine products that support clinical decision making.

Ballard Power Systems Inc. is a developer and manufacturer of proton exchange membrane (PEM) fuel cell products for markets such as heavy-duty motive, portable power, material handling as well as engineering services. Ballard has designed and shipped over 400 MW of fuel cell products to date.

BDSX vs BLDP — Head-to-Head

Bigger by revenue
BDSX
BDSX
1.6× larger
BDSX
$28.8M
$17.7M
BLDP
Higher net margin
BLDP
BLDP
1008.3% more per $
BLDP
994.4%
-13.8%
BDSX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BDSX
BDSX
BLDP
BLDP
Revenue
$28.8M
$17.7M
Net Profit
$-4.0M
$176.5M
Gross Margin
Operating Margin
-6.8%
Net Margin
-13.8%
994.4%
Revenue YoY
40.8%
Net Profit YoY
51.8%
EPS (diluted)
$-3.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BDSX
BDSX
BLDP
BLDP
Q4 25
$28.8M
Q3 25
$21.8M
$17.7M
Q2 25
$20.0M
Q1 25
$18.0M
Q4 24
$20.4M
Q3 24
$18.2M
$-12.3M
Q2 24
$17.9M
Q1 24
$14.8M
Net Profit
BDSX
BDSX
BLDP
BLDP
Q4 25
$-4.0M
Q3 25
$-8.7M
$176.5M
Q2 25
$-11.5M
Q1 25
$-11.1M
Q4 24
$-8.3M
Q3 24
$-10.3M
Q2 24
$-10.8M
Q1 24
$-13.6M
Gross Margin
BDSX
BDSX
BLDP
BLDP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
156.5%
Q2 24
Q1 24
Operating Margin
BDSX
BDSX
BLDP
BLDP
Q4 25
-6.8%
Q3 25
-32.4%
Q2 25
-48.6%
Q1 25
-50.9%
Q4 24
-32.5%
Q3 24
-47.3%
Q2 24
-46.0%
Q1 24
-74.4%
Net Margin
BDSX
BDSX
BLDP
BLDP
Q4 25
-13.8%
Q3 25
-40.0%
994.4%
Q2 25
-57.3%
Q1 25
-61.8%
Q4 24
-40.4%
Q3 24
-56.5%
Q2 24
-60.3%
Q1 24
-91.9%
EPS (diluted)
BDSX
BDSX
BLDP
BLDP
Q4 25
$-3.35
Q3 25
$-1.16
Q2 25
$-0.08
Q1 25
$-0.08
Q4 24
$-5.02
Q3 24
$-1.40
Q2 24
$-0.08
Q1 24
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BDSX
BDSX
BLDP
BLDP
Cash + ST InvestmentsLiquidity on hand
$19.0M
Total DebtLower is stronger
$50.0M
Stockholders' EquityBook value
$-2.5M
Total Assets
$87.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BDSX
BDSX
BLDP
BLDP
Q4 25
$19.0M
Q3 25
$16.6M
Q2 25
$20.7M
Q1 25
$17.6M
Q4 24
$26.2M
Q3 24
$31.4M
Q2 24
$42.2M
Q1 24
$11.5M
Total Debt
BDSX
BDSX
BLDP
BLDP
Q4 25
$50.0M
Q3 25
$50.0M
Q2 25
$50.0M
Q1 25
$40.0M
Q4 24
$40.0M
Q3 24
$40.0M
Q2 24
$40.1M
Q1 24
$40.1M
Stockholders' Equity
BDSX
BDSX
BLDP
BLDP
Q4 25
$-2.5M
Q3 25
$-1.7M
Q2 25
$1.1M
Q1 25
$11.1M
Q4 24
$20.9M
Q3 24
$27.9M
Q2 24
$36.3M
Q1 24
$-5.5M
Total Assets
BDSX
BDSX
BLDP
BLDP
Q4 25
$87.5M
Q3 25
$88.7M
Q2 25
$87.7M
Q1 25
$86.2M
Q4 24
$97.2M
Q3 24
$102.7M
Q2 24
$115.8M
Q1 24
$87.2M
Debt / Equity
BDSX
BDSX
BLDP
BLDP
Q4 25
Q3 25
Q2 25
43.95×
Q1 25
3.62×
Q4 24
1.92×
Q3 24
1.44×
Q2 24
1.10×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BDSX
BDSX
BLDP
BLDP
Operating Cash FlowLast quarter
$778.0K
$5.7M
Free Cash FlowOCF − Capex
$692.0K
FCF MarginFCF / Revenue
2.4%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
0.03×
TTM Free Cash FlowTrailing 4 quarters
$-23.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BDSX
BDSX
BLDP
BLDP
Q4 25
$778.0K
Q3 25
$-8.9M
$5.7M
Q2 25
$-6.6M
Q1 25
$-8.6M
Q4 24
$-4.1M
Q3 24
$-10.7M
$-6.6M
Q2 24
$-18.6M
Q1 24
$-15.3M
Free Cash Flow
BDSX
BDSX
BLDP
BLDP
Q4 25
$692.0K
Q3 25
$-8.9M
Q2 25
$-6.6M
Q1 25
$-8.7M
Q4 24
$-4.9M
Q3 24
$-10.9M
Q2 24
$-20.5M
Q1 24
$-15.5M
FCF Margin
BDSX
BDSX
BLDP
BLDP
Q4 25
2.4%
Q3 25
-41.0%
Q2 25
-33.1%
Q1 25
-48.3%
Q4 24
-24.2%
Q3 24
-60.1%
Q2 24
-114.3%
Q1 24
-104.9%
Capex Intensity
BDSX
BDSX
BLDP
BLDP
Q4 25
0.3%
Q3 25
0.2%
Q2 25
0.3%
Q1 25
0.4%
Q4 24
4.1%
Q3 24
1.3%
Q2 24
10.7%
Q1 24
1.6%
Cash Conversion
BDSX
BDSX
BLDP
BLDP
Q4 25
Q3 25
0.03×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BDSX
BDSX

Diagnostic Tests$25.1M87%
Development Services$3.6M13%

BLDP
BLDP

Segment breakdown not available.

Related Comparisons